The MIXiii Health-Tech.IL 2026 conference opened in Jerusalem on Monday, bringing 1,800 participants from over 40 countries to the International Convention Center. This annual gathering, focused on life sciences and health-tech, highlighted emergency medicine as a field gaining importance due to recent wars and battlefield experience. IATI CEO and President Karin Mayer Rubinstein stated that the Israeli high-tech sector operates within a complex and challenging environment. She cited the security reality, geopolitical uncertainty, and economic challenges as significant factors impacting the industry.
Despite these persistent threats, Israeli high-tech remains a central growth engine for the country’s economy. Mayer Rubinstein emphasized its continued ability to attract international investors and companies. The conference itself, described by organizers as the largest biomedical industry conference in the Middle East, serves as a concrete expression of this strength. Over two days, hundreds of senior figures from global life sciences and digital health industries are meeting with investors and decision-makers. Jerusalem Mayor Moshe Lion, along with India’s Ambassador to Israel Jitender Pal Singh and executives from Teva, attended the opening event. Their presence underscored the international recognition of Israel's technological prowess, even as the nation confronts regional instability.
Innovation Under Siege
The conference agenda specifically included emergency medicine, a critical area directly impacted by the ongoing need for advanced medical responses to conflict. This focus reflects Israel's unique position on the front lines of security challenges. More than 60 investors and 30 venture capital funds from around the world are participating, demonstrating sustained confidence in Israel's innovation ecosystem. This investment occurs despite the "complex and challenging environment" mentioned by Mayer Rubinstein. Mayer Rubinstein noted that Israeli high-tech has repeatedly proven its resilience and ability to adapt. This adaptability is crucial for a nation that consistently faces existential threats.
Global Partnership in Defense
A new IATI TTOs Pitch Session connects technology transfer organizations from leading Israeli research institutions, universities, and hospitals with investors. This initiative aims to strengthen the link between Israeli research, the investment community, and industry. Commercialization companies are presenting new life sciences and healthcare technologies during these sessions. The goal is to turn Israeli innovation into partnerships, investment, and commercial activity, bolstering the nation's strategic capabilities. In a separate event, five biomed startups from Jerusalem presented their developments to executives from leading biomed companies and investment funds. These companies were selected from approximately 300 biomedical firms operating within the city. EMRIS Pharma, a company developing treatments to prevent skin toxicities from cancer therapies, was among those presenting. Such medical advancements contribute to both civilian well-being and military readiness. Mayer Rubinstein affirmed that the conference is part of a broader year-round effort to strengthen Israel’s position in the global innovation arena. This continuous effort is vital for a nation that must constantly innovate to maintain its security and economic independence. She stressed the importance of continuing to tell the story of Israeli innovation to the world, especially "during this period." This narrative reinforces investor confidence and ensures high-tech remains a major growth engine for the Israeli economy in the years ahead, securing its future.